CN106535902B - 用于刺激肠内分泌系统以治疗与其相关的疾病或状况的方法和组合物 - Google Patents

用于刺激肠内分泌系统以治疗与其相关的疾病或状况的方法和组合物 Download PDF

Info

Publication number
CN106535902B
CN106535902B CN201580033333.7A CN201580033333A CN106535902B CN 106535902 B CN106535902 B CN 106535902B CN 201580033333 A CN201580033333 A CN 201580033333A CN 106535902 B CN106535902 B CN 106535902B
Authority
CN
China
Prior art keywords
squalamine
aminosterol
administered
aminosterols
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580033333.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106535902A (zh
Inventor
M·札斯洛夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intel Laboratories Inc
Original Assignee
Intel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intel Corp filed Critical Intel Corp
Priority to CN202110489234.7A priority Critical patent/CN113559108A/zh
Publication of CN106535902A publication Critical patent/CN106535902A/zh
Application granted granted Critical
Publication of CN106535902B publication Critical patent/CN106535902B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201580033333.7A 2014-06-23 2015-06-22 用于刺激肠内分泌系统以治疗与其相关的疾病或状况的方法和组合物 Active CN106535902B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110489234.7A CN113559108A (zh) 2014-06-23 2015-06-22 用于刺激肠内分泌系统以治疗与其相关的疾病或状况的方法和组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462015657P 2014-06-23 2014-06-23
US62/015,657 2014-06-23
US14/329,627 2014-07-11
US14/329,627 US10040817B2 (en) 2013-10-03 2014-07-11 Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
PCT/US2015/036935 WO2015200195A1 (en) 2014-06-23 2015-06-22 Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110489234.7A Division CN113559108A (zh) 2014-06-23 2015-06-22 用于刺激肠内分泌系统以治疗与其相关的疾病或状况的方法和组合物

Publications (2)

Publication Number Publication Date
CN106535902A CN106535902A (zh) 2017-03-22
CN106535902B true CN106535902B (zh) 2021-05-25

Family

ID=54869043

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580033333.7A Active CN106535902B (zh) 2014-06-23 2015-06-22 用于刺激肠内分泌系统以治疗与其相关的疾病或状况的方法和组合物
CN202110489234.7A Pending CN113559108A (zh) 2014-06-23 2015-06-22 用于刺激肠内分泌系统以治疗与其相关的疾病或状况的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110489234.7A Pending CN113559108A (zh) 2014-06-23 2015-06-22 用于刺激肠内分泌系统以治疗与其相关的疾病或状况的方法和组合物

Country Status (19)

Country Link
US (10) US10040817B2 (enExample)
EP (1) EP3157531B1 (enExample)
JP (2) JP6692300B2 (enExample)
CN (2) CN106535902B (enExample)
BR (1) BR112016029917A2 (enExample)
CA (1) CA2951720C (enExample)
CY (1) CY1124554T1 (enExample)
DK (1) DK3157531T3 (enExample)
ES (1) ES2878077T3 (enExample)
HR (1) HRP20211005T1 (enExample)
HU (1) HUE054828T2 (enExample)
LT (1) LT3157531T (enExample)
MX (2) MX382442B (enExample)
PL (1) PL3157531T3 (enExample)
PT (1) PT3157531T (enExample)
RS (1) RS62064B1 (enExample)
SI (1) SI3157531T1 (enExample)
SM (1) SMT202100373T1 (enExample)
WO (1) WO2015200195A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10040817B2 (en) * 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
US20160058730A1 (en) * 2014-08-29 2016-03-03 Cadila Healthcare Limited Pharmaceutical compositions of teriflunomide
WO2018222665A1 (en) * 2017-05-31 2018-12-06 Enterin Laboratories, Inc. Methods and compositions for preventing or treating inflammatory diseases
US11083735B2 (en) * 2017-09-08 2021-08-10 Enterin, Inc. Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions
US11066438B2 (en) 2017-10-30 2021-07-20 Enterin, Inc. Squalamine solid forms and methods of making the same
CA3094977A1 (en) * 2018-03-27 2019-10-03 Enterin, Inc. Methods and compositions for treating hallucinations and conditions related to the same
SG11202012343TA (en) * 2018-06-13 2021-01-28 Enterin Inc Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration
EP3829587A4 (en) * 2018-08-03 2022-07-20 Enterin, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN AND GUESS DISORDERS
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
US20210315907A1 (en) * 2018-08-03 2021-10-14 Enterin, Inc, Compositions and methods for treating brain-gut disorders
EP3829537A4 (en) * 2018-08-03 2022-09-21 Enterin, Inc. LOW DOSAGE INTRANASAL DOSAGE FORMS OF AMINOSTEROL AND METHODS OF USE THEREOF
US20230125585A1 (en) * 2019-08-02 2023-04-27 Enterin, Inc. Dosing protocols and regimens for aminosterol treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028411A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Compounds for sustained release of orally delivered drugs

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192756A (en) 1992-03-18 1993-03-09 The Children's Hospital Of Pennsylvania Aminosterol antibiotic
US5352682A (en) 1993-03-08 1994-10-04 Digestive Care Inc. Compositions containing salts of bile acid-aminosalicylate conjugates
DE69412596T2 (de) 1993-03-10 1999-03-04 Magainin Pharmaceuticals Inc., Plymouth Meeting, Pa. Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel
US5840740A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
US5856535A (en) 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
AU3512595A (en) 1994-09-13 1996-03-29 Magainin Pharmaceuticals, Inc. Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds
US5834453A (en) 1995-05-30 1998-11-10 Lehigh University Methods for the manufacture and use of antimicrobial sterol conjugates
US5795885A (en) 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
ES2216049T3 (es) 1995-06-07 2004-10-16 Genaera Corporation Compuestos de aminosterol utiles como inhibidores del intercambiador de sodio/protones (nhe), metodos y composiciones farmaceuticas que emplean dichos inhibidores y procesos para evaluar la eficacia inhibidora de nhe de dichos compuestos.
US6143738A (en) 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5874597A (en) 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5792635A (en) 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5840936A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5994336A (en) 1995-06-07 1999-11-30 Magainin Pharmaceuticals Inc. Method of inhibiting proliferation of cells by administering an aminosterol compound
US5763430A (en) 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5744453A (en) 1996-01-05 1998-04-28 Mintz; Clifford S. Polyamine conjugates for treatment of infection
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
PT910382E (pt) 1996-04-26 2003-10-31 Genaera Corp Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
US7410959B1 (en) * 2000-07-13 2008-08-12 Genaera Corporation Therapeutic uses for aminosterol compounds
CA2255856C (en) 1996-05-17 2008-05-13 Magainin Pharmaceuticals Inc. Therapeutic uses for an aminosterol compound
AU5194998A (en) 1996-11-01 1998-05-29 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and uses therefor
ATE375359T1 (de) 1998-08-12 2007-10-15 Genaera Corp Aminosterolderivate und ihre verwendungen
US6288089B1 (en) * 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
US6900192B2 (en) 2000-10-06 2005-05-31 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
TR201903603T4 (tr) * 2002-01-28 2019-04-22 Kyowa Hakko Kogyo Kk Hareket bozukluklarının tedavisinde kullanım için A2A reseptörü antagonistleri.
AU2003298514A1 (en) 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US7981876B2 (en) 2005-04-25 2011-07-19 Ohr Pharmaceuticals, Inc. Polymorphic and amorphous salt forms of squalamine dilactate
WO2009032321A2 (en) 2007-09-06 2009-03-12 Genaera Corporation A method for treating diabetes
US8247435B2 (en) * 2009-02-19 2012-08-21 Thornthwaite Jerry T Formulations for treating human and animal diseases
US8729058B2 (en) 2009-10-27 2014-05-20 Michael Zasloff Methods and compositions for treating and preventing viral infections
US8623416B2 (en) 2009-11-25 2014-01-07 Michael Zasloff Formulations comprising aminosterols
JP6165843B2 (ja) 2012-04-20 2017-07-19 オーエイチアール・ファーマシューティカル・インコーポレイテッドＯｈｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌ，Ｉｎｃ． Ｐｔｐ１ｂ関連疾患の処置のためのアミノステロイド化合物
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
EP2934543B1 (en) 2012-12-20 2018-10-31 Mount Desert Island Biological Laboratory Stimulation and enhancement of regeneration of tissues
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028411A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Compounds for sustained release of orally delivered drugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Squalamine Reverses Age and Loperamide Associated Dysmotility in a Mouse Biomarker Model ofConstipation";Kunze, W et al.;《GASTROENTEROLOGY》;20140531;第146卷(第5期);摘要 *

Also Published As

Publication number Publication date
US10040817B2 (en) 2018-08-07
JP7010979B2 (ja) 2022-02-10
HRP20211005T1 (hr) 2021-09-17
US10196420B2 (en) 2019-02-05
SI3157531T1 (sl) 2021-09-30
US20180319837A1 (en) 2018-11-08
US10633413B2 (en) 2020-04-28
US20170326156A1 (en) 2017-11-16
US20190194244A1 (en) 2019-06-27
EP3157531B1 (en) 2021-03-31
EP3157531A1 (en) 2017-04-26
US20190194243A1 (en) 2019-06-27
LT3157531T (lt) 2021-07-12
JP2017519775A (ja) 2017-07-20
MX2021005489A (es) 2021-06-18
MX382442B (es) 2025-03-13
US20190185513A1 (en) 2019-06-20
US10975116B2 (en) 2021-04-13
ES2878077T3 (es) 2021-11-18
EP3157531A4 (en) 2018-05-16
CA2951720A1 (en) 2015-12-30
WO2015200195A1 (en) 2015-12-30
JP6692300B2 (ja) 2020-05-13
BR112016029917A2 (pt) 2017-08-22
MX2016017368A (es) 2017-08-24
CN106535902A (zh) 2017-03-22
RS62064B1 (sr) 2021-07-30
SMT202100373T1 (it) 2021-07-12
JP2020097587A (ja) 2020-06-25
DK3157531T3 (da) 2021-07-05
US20150368290A1 (en) 2015-12-24
US10208080B2 (en) 2019-02-19
HUE054828T2 (hu) 2021-10-28
US20180002370A1 (en) 2018-01-04
CN113559108A (zh) 2021-10-29
US20170327530A1 (en) 2017-11-16
PT3157531T (pt) 2021-07-01
PL3157531T3 (pl) 2021-11-15
US10208079B2 (en) 2019-02-19
US11440936B2 (en) 2022-09-13
CA2951720C (en) 2023-09-26
CY1124554T1 (el) 2022-07-22
US20220220148A1 (en) 2022-07-14
US20180327445A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
CN106535902B (zh) 用于刺激肠内分泌系统以治疗与其相关的疾病或状况的方法和组合物
US11083735B2 (en) Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions
US20240058353A1 (en) Methods for treating gi tract disorders
Camilleri Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.
CN112672743A (zh) 肝病瘙痒症状的治疗
HK1236807B (en) Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
US20200038413A1 (en) Methods of treating parkinson's disease using aminosterol compositions
US20200038414A1 (en) Methods of treating constipation using aminosterol compositions
US20200038417A1 (en) Methods and compositions for treating cognitive impairment
HK40003409A (en) Treatment of prurigo nodularis
PORTENOY et al. ■ MANAGEMENT OF PAIN

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Pennsylvania, USA

Applicant after: Intel Corp.

Address before: Pennsylvania, USA

Applicant before: Intel Laboratories Inc.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210118

Address after: Pennsylvania, USA

Applicant after: Intel Laboratories Inc.

Address before: Pennsylvania, USA

Applicant before: M - Zagreb slooth

GR01 Patent grant
GR01 Patent grant